Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. Fu J et al. J Clin Invest. 2016 Apr 4. pii: 80276. doi: 10.1172/JCI80276. [Epub ahead of print]. Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. Bieghs L et al. PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016. Assessment of tumoral plasma cells in apheresis products for autologous stem…
DetailsItalian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Martino M et al. Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.79. [Epub ahead of print]. Nuances in the Management of Older People With Multiple Myeloma. Pawlyn C et al. Curr Hematol Malig Rep. 2016 Apr 2. [Epub ahead of print]. Management of multiple myeloma in older adults: Gaining ground with…
DetailsLocal radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
Lee JW et al. Radiat Oncol J. 2016 Mar;34(1):59-63. doi: 10.3857/roj.2016.34.1.59. Epub 2016 Mar 30.
(003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Contr(Sol and Decreases Time to Chemotherapy
[No authors listed] Oncology (Williston Park). 2016 Apr 11;30(4 Suppl 1). pii: 216627.
Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma. Ninkovic S et al. Leuk Lymphoma. 2016 Apr 27:1-4. [Epub ahead of print]. A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. Rades D et al. BMC Cancer. 2016 Apr 25;16(1):292. doi: 10.1186/s12885-016-2325-y. A multicenter, retrospective epidemiologic survey of the clinical features and…
DetailsA phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M et al. Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.94. [Epub ahead of print]. Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection.…
DetailsDiagnostic Advances in Multiple Myeloma. Barley K et al. Curr Hematol Malig Rep. 2016 Feb 27. [Epub ahead of print]. Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma. Bolomsky A et al. Leuk Lymphoma. 2016 Mar 21:1-10. [Epub ahead of print]. Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques. Rubini G et…
DetailsMonoclonal gammopathy-associated pure red cell aplasia. Korde N et al, Br J Haematol. 2016 Mar 21. doi: 10.1111/bjh.14012. [Epub ahead of print]. A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. Leung N et al, Clin J Am Soc Nephrol. 2016 Mar 18. pii: CJN.10641015. [Epub ahead of print]. A Case of Cardiac Light Chain Deposition…
DetailsSorafenib for the treatment of multiple myeloma. Gentile M et al. Expert Opin Investig Drugs. 2016 Mar 21. [Epub ahead of print]. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. Gibiansky L et al. J Pharmacokinet Pharmacodyn. 2016 Mar 18. [Epub ahead of print]. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Rotolo A et al. Br J Haematol. 2016…
DetailsMultiple myeloma cancer stem cells. Gao M et al. Oncotarget. 2016 Mar 17. doi: 10.18632/oncotarget.8154. [Epub ahead of print]. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Tang M et al. Clin Cancer Res. 2016 Mar 22. pii: clincanres.2793.2015. [Epub ahead of print]. Multiple myeloma in the marrow: pathogenesis and treatments. Fairfield H et al. Ann N Y…
DetailsTreatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Sonneveld P et al. Blood. 2016 Mar 21. pii: blood-2016-01-631200. [Epub ahead of print]. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Wahaib K et al. Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487. Haematological cancer: PomCyDex – a lower-cost option in refractory myeloma?…
Details